Search clinical trials for: Canagliflozin (JNJ-28431754)

Total 976 results

Johnson & Johnson Pharmaceutical Research & Development...

Terminated

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of JNJ-38431055 in Volunteers With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2
Janssen-Cilag International NV

Completed

A Single Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JNJ-42165279 in Healthy Male Participants

Healthy Volunteers | Pharmacokinetics

Belgium
Janssen Research & Development, LLC

Active, not recruiting

A Study of JNJ-77242113 for the Treatment of Participants With Plaque Psoriasis Involving Special Areas (Scalp, Genital, and/or Palms of the Hands and the Soles of the Feet) (ICONIC-TOTAL)

Plaque Psoriasis

United States, Korea, Republic of, Hungary, United Kingdom, Canada, Germany, Poland, Turkey, Taiwan, Spain, Argentina
Janssen Research & Development, LLC

Terminated

A Study of JNJ-69095897 in Healthy Participants

Healthy

Netherlands
Janssen Research & Development, LLC

Completed

A Study of JNJ-68179280 in Healthy Participants

Healthy

United States
Janssen Research & Development, LLC

Completed

A Single Ascending Dose Study of JNJ-88260237 in Healthy Participants

Healthy

United States
Janssen Research & Development, LLC

Withdrawn

A Study of JNJ-77474462 (Bermekimab) in Healthy Chinese Participants

Healthy

China
Janssen Research & Development, LLC

Completed

A Study to Investigate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-63733657 in Healthy Subjects and Subjects With Alzheimer's Disease

Alzheimer Disease

Belgium, Spain, Netherlands, Germany
Janssen Pharmaceutica N.V., Belgium

Terminated

A Study of JNJ-64140284 in Healthy Male Participants (AMPAR)

Healthy

Belgium
Janssen Pharmaceutical K.K.

Withdrawn

A Study of JNJ-75105186 in Healthy Japanese and Chinese Participants

Healthy

Japan
Janssen Research & Development, LLC

Withdrawn

A Study of JNJ-64304500 in Participants With Alopecia Areata

Alopecia Areata

United States, Japan, France, Australia
Janssen Research & Development, LLC

No longer available

Pre-Approval Access to Pimodivir for the Treatment of Patients With H7N9 Influenza A Infection

H7N9 Subtype of Influenza A Virus
Janssen Research & Development, LLC

Completed

A Study of JNJ-70033093 (BMS-986177) in Healthy Adult Participants

Healthy

United States
Janssen-Cilag International NV

Completed

Study to Investigate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-61393215 in Healthy Participants

Healthy

Netherlands
Janssen Sciences Ireland UC

Completed

A Study of JNJ-73763989 in Healthy Japanese Adult Participants

Healthy

United Kingdom
Janssen Research & Development, LLC

Completed

To Assess the Pharmacokinetics and Safety of Single Doses of JNJ-54452840 in Healthy Japanese and Caucasian Participants

Healthy

United States
Johnson & Johnson Pharmaceutical Research & Development...

Completed

JNJ-41443532 Sex, Race, and Age Pharmacokinetic (PK) Study

Healthy

United States
Janssen R&D Ireland

Completed

A Study in Healthy Participants Investigating the Safety, Tolerability and Plasma Pharmacokinetics (PK) of Single Oral Doses of JNJ-47910382

Hepatitis C Virus Infection

Germany
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study of the Effects of JNJ-26489112 on the Photic Induced Paroxysmal Electroencephalogram (EEG) Response in Patients With Photosensitive Epilepsy

Photosensitive Epilepsy
Janssen Research & Development, LLC

Completed

A Two-Part Infant Study for Early Diagnosis of Respiratory Syncytial Virus (RSV) and Evaluation of JNJ-53718678 in RSV Acute Respiratory Tract Disease

Respiratory Syncytial Viruses

Taiwan, Belgium, United Kingdom, Argentina, Panama
Janssen Research & Development, LLC

Completed

A Safety and Efficacy Study of JNJ-42165279 in Participants With Social Anxiety Disorder

Phobic Disorders

United States, Australia, Canada
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Investigate How JNJ-39758979 May Affect the Plasma Levels of Methotrexate in Rheumatoid Arthritis Participants

Rheumatoid Arthritis

United States, Germany
Janssen Research & Development, LLC

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-42165279 in Healthy Young and Elderly Participants

Healthy

Belgium
Janssen Research & Development, LLC

Completed

A Study of JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis (SUMMIT)

Plaque Psoriasis

United States, Canada, Germany, France, Spain, Poland
Janssen Research & Development, LLC
Bristol-Myers Squibb

Completed

A Study of JNJ-70033093 in Healthy Participants

Healthy

Belgium
Janssen Research & Development, LLC
Bristol-Myers Squibb

Completed

A Study of JNJ-70033093 (BMS-986177) Versus Subcutaneous Enoxaparin in Participants Undergoing Elective Total Knee Replacement Surgery (AXIOMATIC-TKR)

Arthroplasty, Replacement, Knee

Israel, Belgium, Italy, United States, Spain, Hungary, Portugal, Russian Federation, Japan, Turkey, Ukraine, Greece, Poland, Argentina, Brazil, Bulgaria, Canada, South Africa
Janssen Research & Development, LLC

Recruiting

A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis

Myasthenia Gravis

United States, Japan, Netherlands, Poland
Janssen Research & Development, LLC

Completed

A Phase 1b Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of JNJ-64565111 in Participants With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

United States
Janssen Research & Development, LLC

Withdrawn

A Study of JNJ-64304500 Following Subcutaneous Injection in Healthy Chinese Adult Participants

Healthy

China
Janssen Research & Development, LLC

No longer available

Individual Patient Investigational New Drug (IND) Expanded Access Program of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy for Participant With Multiple Myeloma

Multiple Myeloma
Janssen Research & Development, LLC

Completed

A Study of Nipocalimab in Healthy Male and Female Participants

Healthy

Netherlands
Janssen Research & Development, LLC

Terminated

A Study of JNJ-53718678 in Participants With Hepatic Impairment

Hepatic Impairment

United States
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Pharmacokinetics Study to Evaluate Safety and Tolerability of JNJ-37822681 in Participants With Stable Schizophrenia

Schizophrenia

Belgium, Germany, Russian Federation, Slovakia, Sweden
Alios Biopharma Inc.

Completed

A Study of Orally Administered JNJ-440 to Evaluate the Safety, Tolerability, and Pharmacokinetics After Single Ascending Doses Including Food Effect Evaluation; After Multi-Day Dosing in Healthy Participants; and After Multiple (Ascending) Doses in Participants With Chronic Hepatitis B

Chronic Hepatitis B

Korea, Republic of, Moldova, Republic of, New Zealand, Thailand, Ukraine
Janssen Sciences Ireland UC

Completed

An Efficacy, Safety, and Pharmacokinetics Study of JNJ-56136379 in Participants With Chronic Hepatitis B Virus Infection

Hepatitis B

United States, Korea, Republic of, France, Belgium, Italy, Taiwan, United Kingdom, Thailand, Malaysia, China, Spain, Canada, Germany, Japan, Russian Federation, Turkey, Ukraine, Poland, Hong Kong
Janssen Research & Development, LLC

Completed

A Safety, Tolerability and Pharmacokinetics Study of a Single Intravenous Dose of JNJ-49122944 in Healthy Male Participants

Healthy

Belgium
Janssen Research & Development, LLC
Pharmacyclics LLC.

Terminated

A Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Participants With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma

Lymphoma, Non-Hodgkin

United States, France, Poland, United Kingdom, Germany, Taiwan, Spain, Bulgaria, Romania, Turkey, Ukraine, Canada, Korea, Republic of, Netherlands, Russian Federation, Belgium, Brazil, Hungary, Czechia, Sweden
Janssen Research & Development, LLC

Active, not recruiting

A Study of JNJ-73763989, JNJ-64300535, and Nucleos(t)Ide Analogs in Virologically Suppressed, Hepatitis B e Antigen (HBeAg)- Negative Participants With Chronic Hepatitis B Virus Infection (OSPREY)

Hepatitis B, Chronic

France, Belgium, Italy, United Kingdom, Poland, Spain, New Zealand, Taiwan
Janssen Research & Development, LLC

Recruiting

A Study of Nipocalimab in Pregnancies at Risk for Severe Hemolytic Disease of the Fetus and Newborn (HDFN) (AZALEA)

Hemolytic Disease of the Fetus and Newborn

Israel, Japan, Australia, United States, United Kingdom, Brazil
Janssen Research & Development, LLC

Recruiting

Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

United States, China, Taiwan, Korea, Republic of, Japan, France, Portugal, Spain, Czechia, Poland, Greece, United Kingdom
Janssen Research & Development, LLC

Recruiting

A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis

Myasthenia Gravis

United States, Korea, Republic of, Japan, Taiwan, Denmark, Germany, Czechia, China, Spain, Belgium, Canada, Mexico, Poland, Italy, France, Australia, Sweden
Janssen Research & Development, LLC

Completed

A Study of JNJ-70033093 (Milvexian) in Healthy Adult Participants

Healthy

United States
Janssen Vaccines & Prevention B.V.

Completed

An Exploratory Study to Evaluate the Prophylactic Efficacy of a Single Immunization of Ad26.RSV.preF Against Respiratory Syncytial Virus Infection in a Virus Challenge Model in Healthy 18 to 50 Year-old Adults

Healthy

United Kingdom
Janssen Pharmaceutical K.K.

Completed

A Study of JNJ-61393215 in Healthy Japanese Male Participants

Healthy

Japan
Janssen Research & Development, LLC

Completed

A Proof-of-concept Study of the Efficacy and Safety of Nipocalimab in Participants With Active Rheumatoid Arthritis

Arthritis, Rheumatoid

United Kingdom, United States, Spain, Germany, Poland
Janssen Research & Development, LLC

Terminated

A Study of Rilematovir (JNJ-53718678) in Adult Outpatients With Respiratory Syncytial Virus (RSV) Infection (PRIMROSE)

Respiratory Syncytial Virus

United States, Germany, Italy, Ukraine, Spain, Sweden, Thailand, Argentina, Bulgaria, Japan, Poland, Canada, Hungary, South Africa
Janssen Research & Development, LLC

Terminated

Study to Examine the Cytokine Levels, Gene Expression and Safety of a Single Nasal Dose of JNJ-43260295, in Healthy Participants, and Atopic Participants With Mild to Mild-Persistent Asthma

Healthy | Asthma

United States
Johnson & Johnson Pharmaceutical Research & Development...

Completed

Ketamine Challenge Study With JNJ-40411813

Confusion | Schizophrenia | Perceptual Disorders

Germany
Janssen Research & Development, LLC

Completed

A Study to Investigate the Safety, Tolerability, Food Effect, and Pharmacokinetics of JNJ-54416076 in Healthy Participants

Healthy

Germany
Janssen Research & Development, LLC

Recruiting

A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis

Relapsed or Refractory Multiple Myeloma | Previously Treated Amyloid Light-chain (AL) Amyloidosis

Belgium, United States, United Kingdom, Spain, France, Netherlands

Search clinical trials for: Canagliflozin (JNJ-28431754)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ethiopia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations